Q4 2023 Earnings Summary
- Danaher has strengthened its portfolio with the acquisition of Abcam, expanding its presence in the highly attractive proteomics market and furthering its strategy to accelerate drug discovery.
- Management expects destocking in bioprocessing to be largely completed in the first half of 2024, anticipating a return to mid- to high single-digit growth in the second half, exiting the year with high single-digit or better core growth.
- Danaher projects an adjusted operating profit margin improvement of approximately 50 basis points in 2024, driven by proactive cost structure improvements, including headcount reductions.
- Weakness in the China market: Danaher expects the China market to be down high single digits in 2024 due to challenging macroeconomic conditions, which may be more severe than in the healthcare market. This ongoing weakness could negatively impact revenue growth.
- Decline in the Bioprocessing segment: The Bioprocessing business is anticipated to decline in the first half of 2024, with no significant inflection modeled for the year. Ongoing inventory destocking and lower customer demand suggest continued challenges in this key business segment.
- Softness in Life Sciences Instrumentation: The Life Sciences Instrumentation business is projected to be down low single digits for 2024. Lower levels of demand from pharma and biotech customers, coupled with continued normalization after anomalous buying during the pandemic, indicate sustained softness in this segment.
-
Bioprocessing Outlook and Destocking Impact
Q: What is the outlook for bioprocessing, and when will destocking end?
A: Management expects the bioprocessing business to be down low single digits in 2024, with the first half resembling the second half of 2023—down mid- to high teens—and returning to mid- to high single-digit growth in the second half as destocking in North America and Europe largely completes. They anticipate exiting the year with high single-digit or better core growth in bioprocessing. -
Margin Expansion and Cost Structure
Q: How will cost-saving measures impact margins in 2024 and beyond?
A: Despite lower volumes, management projects an adjusted operating margin increase of 50 basis points for 2024, reaching approximately 29%. They achieved $350 million in cost savings last year through headcount reductions and facility consolidations, which offsets volume declines and contributes to durable margin expansion going forward. -
China Market Outlook
Q: How is the China market performing, and what are the expectations?
A: China is expected to be down high single digits in 2024 due to a challenging macro environment and weaker activity levels, particularly in biotechnology and life sciences. However, management remains confident in China's long-term attractiveness, citing government prioritization of healthcare and the development of its pharmaceutical industry. They anticipate that current headwinds will resolve in the midterm. -
Book-to-Bill Expectations and Backlog
Q: What are the book-to-bill expectations and implications for backlog?
A: Management does not anticipate the book-to-bill ratio to exceed 1 in any quarter of 2024, though it may get close in the second half. They are starting the year with a backlog consistent with historical levels and expect gradual improvements as destocking subsides. The second half of 2024 assumes a $250 million year-over-year increase in bioprocessing revenue on a $6 billion business, which they consider modest. -
Life Sciences Instrumentation Outlook
Q: What is the outlook for Life Sciences Instrumentation in 2024?
A: The Life Sciences Instrumentation business is expected to be down low single digits in 2024, with a softer first half due to significant prior-year comps, particularly from the China loan program, and continued normalization of demand in pharma and biotech. Improvement is anticipated in the second half as comparisons ease, but overall activity levels are stabilizing at lower levels. -
Customer Inventory Levels and Recovery Pace
Q: Are customers signaling they've reduced inventory too much, and could there be a faster recovery?
A: Anecdotal evidence suggests some customers may have gotten too lean on inventory, and management is seeing early signs of improvement in order patterns. However, they are not modeling a V-shaped recovery, lacking sufficient confidence in a significant inflection. They expect destocking to be largely behind by the first half's end, leading to better performance in the second half. -
Diagnostics Business and Respiratory Revenue
Q: Why is Diagnostics growth slowing despite strong base business performance?
A: The Diagnostics segment is projected to grow up low single digits in 2024. The base Diagnostics business, excluding respiratory products, continues to perform well, expected to grow mid-single digits. The slower overall growth is due to declining respiratory revenues, decreasing from $1.9 billion in 2023 to $1.6 billion in 2024, representing a tough comparison to the prior year. -
Abcam Acquisition and Capital Deployment
Q: What is the update on Abcam and plans for capital deployment post-Veralto spin?
A: Management is pleased with the early progress of the Abcam integration, noting a strong finish to the year and focused implementation of the Danaher Business System. Post-Veralto spin, they emphasize a strong balance sheet and intend to continue actively deploying capital to strengthen their portfolio through strategic acquisitions.